Exactech Inc.
http://www.exac.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Exactech Inc.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Remibrutinib REMIXes The Itch Record
Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.
Trials In Focus: Patient Advocacy Group Takes Trial Diversity To Capitol Hill
The Foundation for Sarcoidosis Research briefed US Congress on participation by Black patients in sarcoidosis and other rare disease trials. Also, the US FDA issued a draft guidance on psychedelic drug trials; Insilico is taking its AI-discovered IPF drug into Phase II; and Compugen and Jasper dosed patients in their oncology trials.
Company Information
- Industry
- Distributors
- Contract Manufacturing Organization
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Blue Ortho SAS
- Exactech Australia Pty Ltd
- TPG Capital
- XpandOrtho, Inc.
- Exactech Italia
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice